CECCON, MONICA

CECCON, MONICA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 29 (tempo di esecuzione: 0.046 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 01 - Articolo su rivista 2022 Mologni, LucaOrsato, AlexandreCeccon, MonicaViltadi, MichelaVece, VitoGambacorti-Passerini, Carlo +
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 01 - Articolo su rivista 2022 Mologni, LucaCeccon, MonicaViltadi, MichelaVece, VitoGambacorti-Passerini, Carlo +
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma, GGVilla, MMauri, MCrespiatico, IFontana, DMastini, CMagistroni, VCeccon, MRedaelli, SMassimino, LPiazza, RGambacorti Passerini, CMologni, L +
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 02 - Intervento a convegno 2021 Villa, MMauri, MMagistroni, VCeccon, MRedaelli, SCrespiatico, IFontana, DMastini, CPiazza, RGambacorti Passerini, CMologni, L +
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 01 - Articolo su rivista 2021 Ceccon M.Mologni L.Gambacorti Passerini C. +
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 02 - Intervento a convegno 2018 GEETA, GEETARedaelli, SCeccon, MGambacorti-Passerini, CMologni, L +
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 01 - Articolo su rivista 2018 Redaelli, SaraCeccon, MonicaSharma, Geeta GMastini, CristinaMauri, MarioMassimino, LucaCordani, NicolettaFarina, FrancescaPiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 01 - Articolo su rivista 2018 Ceccon, MonicaMauri, MarioMassimino, LucaPiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 02 - Intervento a convegno 2017 Farina, FCeccon, MMori, SVerga, LBorin, LMMologni, LFontana, DGEETA, GEETAPiazza, RGambacorti-Passerini, C
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 01 - Articolo su rivista 2016 CECCON, MONICAMOLOGNI, LUCABOMBELLI, SILVIARIGOLIO, ROBERTACASATI, COSTANZAMASTINI, CRISTINAGAMBACORTI PASSERINI, CARLO +
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 01 - Articolo su rivista 2016 REDAELLI, SARACECCON, MONICAANTOLINI, LAURARIGOLIO, ROBERTAPIROLA, ALESSANDRAPERONACI, MARCOGAMBACORTI PASSERINI, CARLOMOLOGNI, LUCA
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 02 - Intervento a convegno 2015 Ceccon, MMologni, LBombelli, SRigolio, RCASATI, COSTANZAGambacorti Passerini, C +
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 02 - Intervento a convegno 2015 Mologni, LCeccon, MFontana, DPirola, APiazza, RGambacorti-Passerini, C
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 01 - Articolo su rivista 2015 FONTANA, DILETTACECCON, MONICAGAMBACORTI PASSERINI, CARLOMOLOGNI, LUCA
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 99 - Altro 2015 Ceccon M.Mologni L.Piazza R.Pirola A.Fontana D. +
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 01 - Articolo su rivista 2015 REDAELLI, SARAPERINI, PIETROCECCON, MONICAPIAZZA, ROCCO GIOVANNIRIGOLIO, ROBERTAMAURI, MARIOGAMBACORTI PASSERINI, CARLO +
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 01 - Articolo su rivista 2015 MOLOGNI, LUCACECCON, MONICAPIROLA, ALESSANDRAPIAZZA, ROCCO GIOVANNIGAMBACORTI PASSERINI, CARLO +
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 01 - Articolo su rivista 2015 CECCON, MONICAGAMBACORTI PASSERINI, CARLO +
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 02 - Intervento a convegno 2015 Redaelli, SCeccon, MPirola, APeronaci, MGambacorti-Passerini, CMologni, L
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 01 - Articolo su rivista 2015 CECCON, MONICAMOLOGNI, LUCAPIAZZA, ROCCO GIOVANNIPIROLA, ALESSANDRAFONTANA, DILETTAGAMBACORTI PASSERINI, CARLO +